United States: These 44 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 20, 2026
Generic Entry Controlled by: United States Patent 7,960,370

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-five patent family members in forty-one countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: tafamidis meglumine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2026
Generic Entry Controlled by: United States Patent 7,214,695

VYNDAQEL is a drug marketed by Foldrx Pharms. There are two patents protecting this drug.

This drug has thirty-five patent family members in seventeen countries. There has been litigation on patents covering VYNDAQEL

See drug price trends for VYNDAQEL.

The generic ingredient in VYNDAQEL is tafamidis meglumine. One supplier is listed for this generic product. Additional details are available on the tafamidis meglumine profile page.

Generic name: afamelanotide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 08, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SCENESSE is a drug marketed by Clivunel Inc. There are two patents protecting this drug.

This drug has thirty-four patent family members in eighteen countries.

See drug price trends for SCENESSE.

The generic ingredient in SCENESSE is afamelanotide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the afamelanotide profile page.

Generic name: ferric carboxymaltose
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 31, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

INJECTAFER is a drug marketed by Am Regent. There are six patents protecting this drug.

This drug has seventy-one patent family members in thirty-two countries. There has been litigation on patents covering INJECTAFER

See drug price trends for INJECTAFER.

The generic ingredient in INJECTAFER is ferric carboxymaltose. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ferric carboxymaltose profile page.

Generic name: retapamulin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 14, 2027
Generic Entry Controlled by: United States Patent 7,875,630

ALTABAX is a drug marketed by Almirall. There is one patent protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. Additional details are available on the retapamulin profile page.

Generic name: sinecatechins
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 02, 2026
Generic Entry Controlled by: United States Patent 5,795,911

VEREGEN is a drug marketed by Ani Pharms. There are two patents protecting this drug.

This drug has thirty-one patent family members in twenty countries. There has been litigation on patents covering VEREGEN

See drug price trends for VEREGEN.

The generic ingredient in VEREGEN is sinecatechins. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sinecatechins profile page.

Generic name: loxapine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 23, 2026
Generic Entry Controlled by: United States Patent 8,387,612

ADASUVE is a drug marketed by Alexza Pharms. There is one patent protecting this drug.

This drug has twenty-one patent family members in six countries. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this API. Additional details are available on the loxapine profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 01, 2027
Generic Entry Controlled by: United States Patent 7,531,623

VIBATIV is a drug marketed by Cumberland. There is one patent protecting this drug.

This drug has thirty-three patent family members in eighteen countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: teduglutide recombinant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 16, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GATTEX KIT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in seven countries. There has been litigation on patents covering GATTEX KIT

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this API. Additional details are available on the teduglutide recombinant profile page.

Generic name: omacetaxine mepesuccinate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 26, 2026
Generic Entry Controlled by: United States Patent 6,987,103

SYNRIBO is a drug marketed by Teva Pharms Intl. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in twelve countries.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. Additional details are available on the omacetaxine mepesuccinate profile page.

Generic name: fluciclovine f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: United States Patent 10,010,632

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.

This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

Generic name: gallium dotatoc ga-68
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 21, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GALLIUM DOTATOC GA 68 is a drug marketed by

The generic ingredient in GALLIUM DOTATOC GA 68 is gallium dotatoc ga-68. There are sixteen drug master file entries for this API. Additional details are available on the gallium dotatoc ga-68 profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 12, 2027
Generic Entry Controlled by: United States Patent 10,391,075

RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.

This drug has forty-three patent family members in fourteen countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: golodirsen
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.

This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.

Generic name: brilliant blue g
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TISSUEBLUE is a drug marketed by Dutch Ophthalmic.

The generic ingredient in TISSUEBLUE is brilliant blue g. One supplier is listed for this generic product. Additional details are available on the brilliant blue g profile page.

Generic name: ivabradine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: United States Patent 7,867,996

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

Generic name: mipomersen sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 29, 2027
Generic Entry Controlled by: United States Patent 7,511,131

KYNAMRO is a drug marketed by Kastle Theraps Llc. There is one patent protecting this drug.

This drug has forty-five patent family members in eleven countries. There has been litigation on patents covering KYNAMRO

See drug price trends for KYNAMRO.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

Generic name: pasireotide diaspartate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 14, 2026
Generic Entry Controlled by: United States Patent 7,473,761

SIGNIFOR is a drug marketed by Recordati Rare. There are four patents protecting this drug.

This drug has eighty-seven patent family members in thirty-nine countries.

See drug price trends for SIGNIFOR.

The generic ingredient in SIGNIFOR is pasireotide diaspartate. One supplier is listed for this generic product. Additional details are available on the pasireotide diaspartate profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-five patent family members in twenty-eight countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: olodaterol hydrochloride; tiotropium bromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 19, 2027
Generic Entry Controlled by: United States Patent 7,727,984

STIOLTO RESPIMAT is a drug marketed by Boehringer Ingelheim. There are eight patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty countries. There has been litigation on patents covering STIOLTO RESPIMAT

See drug price trends for STIOLTO RESPIMAT.

The generic ingredient in STIOLTO RESPIMAT is olodaterol hydrochloride; tiotropium bromide. One supplier is listed for this generic product. Additional details are available on the olodaterol hydrochloride; tiotropium bromide profile page.

Generic name: olodaterol hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 19, 2027
Generic Entry Controlled by: United States Patent 7,727,984

STRIVERDI RESPIMAT is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.

This drug has seventy-six patent family members in thirty-seven countries. There has been litigation on patents covering STRIVERDI RESPIMAT

See drug price trends for STRIVERDI RESPIMAT.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this generic product. Additional details are available on the olodaterol hydrochloride profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: United States Patent 7,241,805

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 21, 2026
Generic Entry Controlled by: United States Patent 8,093,423

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: triclabendazole
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 13, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EGATEN is a drug marketed by Novartis.

The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the triclabendazole profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 11, 2026
Generic Entry Controlled by: United States Patent 7,326,708

JUVISYNC is a drug marketed by Merck Sharp Dohme. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-two patent family members in forty countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2026
Generic Entry Controlled by: United States Patent 8,071,577

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: amifampridine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RUZURGI is a drug marketed by One tentatively approved generic is ready to enter the market.

See drug price trends for RUZURGI.

The generic ingredient in RUZURGI is amifampridine. Additional details are available on the amifampridine profile page.

Generic name: aliskiren hemifumarate; valsartan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 03, 2026
Generic Entry Controlled by: United States Patent 8,168,616

VALTURNA is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has ninety-three patent family members in thirty-one countries.

The generic ingredient in VALTURNA is aliskiren hemifumarate; valsartan. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; valsartan profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 14, 2026
Generic Entry Controlled by: United States Patent 11,179,402

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: mechlorethamine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 07, 2026
Generic Entry Controlled by: United States Patent 7,838,564

VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

See drug price trends for VALCHLOR.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.

Generic name: histrelin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: United States Patent 8,062,652

SUPPRELIN LA is a drug marketed by Endo Operations. There is one patent protecting this drug.

This drug has three patent family members in three countries.

See drug price trends for SUPPRELIN LA.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the histrelin acetate profile page.

Generic name: fluticasone furoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 01, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2026
Generic Entry Controlled by: United States Patent 7,550,433

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 03, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NUCYNTA is a drug marketed by Collegium Pharm Inc. There are three patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 24, 2026
Generic Entry Controlled by: United States Patent 9,629,959

OTREXUP is a drug marketed by Assertio Speclty. There are fifteen patents protecting this drug.

This drug has thirty-nine patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 13, 2026
Generic Entry Controlled by: United States Patent 8,114,833

SAXENDA is a drug marketed by Novo. There are two patents protecting this drug.

This drug has sixty-three patent family members in twenty-seven countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 13, 2026
Generic Entry Controlled by: United States Patent 8,114,833

VICTOZA is a drug marketed by Novo Nordisk Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Additional details are available on the liraglutide recombinant profile page.

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SOLUPREP is a drug marketed by 3m Health Care.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 27, 2025
Generic Entry Controlled by: United States Patent 7,994,364

NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are three patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in twenty-seven countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: tivozanib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 10, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

FOTIVDA is a drug marketed by Aveo Pharms. There are three patents protecting this drug.

This drug has fifty-five patent family members in twenty-six countries. There has been litigation on patents covering FOTIVDA

See drug price trends for FOTIVDA.

The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tivozanib hydrochloride profile page.

Generic name: voclosporin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 22, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LUPKYNIS is a drug marketed by Aurinia. There are three patents protecting this drug.

This drug has one hundred and ninety-seven patent family members in forty countries. There has been litigation on patents covering LUPKYNIS

See drug price trends for LUPKYNIS.

The generic ingredient in LUPKYNIS is voclosporin. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the voclosporin profile page.

Generic name: drospirenone; estetrol
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 15, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NEXTSTELLIS is a drug marketed by Mayne Pharma. There are seven patents protecting this drug.

This drug has two hundred and twenty-nine patent family members in fifty-one countries.

See drug price trends for NEXTSTELLIS.

The generic ingredient in NEXTSTELLIS is drospirenone; estetrol. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the drospirenone; estetrol profile page.

Generic name: leuprolide mesylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 16, 2027
Generic Entry Controlled by: United States Patent 10,646,572

CAMCEVI KIT is a drug marketed by Accord. There are five patents protecting this drug.

This drug has thirty-nine patent family members in nineteen countries.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the leuprolide mesylate profile page.

Generic name: estradiol; norethindrone acetate; relugolix
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 28, 2026
Generic Entry Controlled by: United States Patent 7,300,935

MYFEMBREE is a drug marketed by Sumitomo Pharma Am. There are seven patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-six countries. There has been litigation on patents covering MYFEMBREE

See drug price trends for MYFEMBREE.

The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix. There are seventy-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the estradiol; norethindrone acetate; relugolix profile page.

Generic name: albuterol sulfate; budesonide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 10, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

AIRSUPRA is a drug marketed by Astrazeneca. There is one patent protecting this drug.

This drug has one hundred and ninety-two patent family members in thirty-two countries. There has been litigation on patents covering AIRSUPRA

See drug price trends for AIRSUPRA.

The generic ingredient in AIRSUPRA is albuterol sulfate; budesonide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the albuterol sulfate; budesonide profile page.

Generic name: phenylephrine hydrochloride; tropicamide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 05, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MYDCOMBI is a drug marketed by Eyenovia. There are three patents protecting this drug.

This drug has forty-four patent family members in fourteen countries.

The generic ingredient in MYDCOMBI is phenylephrine hydrochloride; tropicamide. There are twenty-one drug master file entries for this API. Additional details are available on the phenylephrine hydrochloride; tropicamide profile page.

Generic name: magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUFLAVE is a drug marketed by Braintree Labs. There are three patents protecting this drug.

This drug has one patent family member in one country.

See drug price trends for SUFLAVE.

The generic ingredient in SUFLAVE is magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate profile page.

Generic name: norgestrel
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

OPILL is a drug marketed by Laboratoire Hra.

See drug price trends for OPILL.

The generic ingredient in OPILL is norgestrel. There are twenty-five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the norgestrel profile page.

Generic name: acetaminophen; ibuprofen sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

COMBOGESIC IV is a drug marketed by Hikma. There are six patents protecting this drug.

This drug has seventy patent family members in thirty-one countries.

The generic ingredient in COMBOGESIC IV is acetaminophen; ibuprofen sodium. There are sixty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the acetaminophen; ibuprofen sodium profile page.

Generic name: technetium tc-99m labeled carbon
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 29, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TECHNEGAS KIT is a drug marketed by Cyclomedica.

The generic ingredient in TECHNEGAS KIT is technetium tc-99m labeled carbon. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the technetium tc-99m labeled carbon profile page.

Generic name: acetylcysteine lysine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LEGUBETI is a drug marketed by Galephar.

The generic ingredient in LEGUBETI is acetylcysteine lysine. There are three drug master file entries for this API. Additional details are available on the acetylcysteine lysine profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: United States Patent 9,763,953

ZUNVEYL is a drug marketed by Alpha Cognition. There are three patents protecting this drug.

This drug has twenty-six patent family members in seventeen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.